Brenda Kirpach
A5044983885- Antiplatelet Therapy and Cardiovascular Diseases
- Inflammatory mediators and NSAID effects
- Blood Pressure and Hypertension Studies
- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
- Dementia and Cognitive Impairment Research
- Cancer, Lipids, and Metabolism
- Eicosanoids and Hypertension Pharmacology
- Atrial Fibrillation Management and Outcomes
- Mobile Health and mHealth Applications
- Frailty in Older Adults
- Chronic Disease Management Strategies
- Health disparities and outcomes
- Hormonal Regulation and Hypertension
- COVID-19 and Mental Health
- Stress Responses and Cortisol
- Sodium Intake and Health
- Neurological Disease Mechanisms and Treatments
- Lung Cancer Treatments and Mutations
- Health, Environment, Cognitive Aging
- Mental Health Research Topics
- Data Quality and Management
- Infection Control and Ventilation
- Nutrition and Health in Aging
- Advanced Causal Inference Techniques
Hennepin Healthcare Research Institute
2018-2024
Berman Center for Outcomes and Clinical Research
2007-2024
Hennepin County Medical Center
2016-2022
Curtin University
2020-2021
University of Iowa
2020
Rush University Medical Center
2020
Wake Forest University
2020
University of Tasmania
2020
Monash University
2020
University of Pittsburgh
2020
Data for front-line health-care workers and risk of COVID-19 are limited. We sought to assess among compared with the general community effect personal protective equipment (PPE) on risk.
Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in primary disease unclear, especially older persons, who have an increased risk.
In the primary analysis of Aspirin in Reducing Events Elderly (ASPREE) trial, now published Journal, we report that daily use aspirin did not provide a benefit with regard to end point disability-free survival among older adults. A numerically higher rate secondary death from any cause was observed than placebo.
Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years daily low-dose therapy would extend disability-free seniors unclear.From 2010 through 2014, we enrolled community-dwelling Australia and United States who were 70 age or (or ≥65 among blacks Hispanics States) did not have cardiovascular disease, dementia, physical disability. Participants randomly assigned receive 100 mg per day enteric-coated placebo orally. The primary...
The rapid pace of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) presents challenges to robust collection population-scale data address this global health crisis. We established COronavirus Pandemic Epidemiology (COPE) Consortium unite scientists with expertise in big research and epidemiology develop COVID Symptom Study, previously known as Tracker, mobile application. This application-which offers on risk factors, predictive...
There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin Reducing Events the Elderly (ASPREE) is a placebo-controlled trial low-dose that will determine whether 5 years daily 100-mg enteric-coated extends disability-free and dementia-free life healthy population these benefits outweigh risks. Set care, this randomized double-blind has composite endpoint death, incident dementia or persistent physical disability. Participants aged 70+...
To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, Alzheimer disease (AD), mild cognitive impairment (MCI), and decline in older individuals.
Abstract Background ASPirin in Reducing Events the Elderly, a randomized, double-blind, placebo-controlled trial of daily low-dose aspirin (100 mg) older adults, showed an increase all-cause mortality, primarily due to cancer. In contrast, prior randomized controlled trials, mainly involving younger individuals, demonstrated delayed cancer benefit with aspirin. We now report detailed analysis incidence and mortality. Methods 19 114 Australian US community-dwelling participants aged 70 years...
Objective This study was conducted to estimate prevalence rates and factors associated with depressive symptoms indexed by the Centre for Epidemiological Studies‐Depression (CES‐D‐10) score in a large sample of community‐dwelling healthy older adults from Australia United States. Convergent divergent validity CES‐D‐10 were also examined. Methods A total 19 114 individuals aged greater than or equal 65 years old enrolled primary prevention clinical trial. Depressive classified using 8 10....
Rationale Aspirin has positive and negative effects on a number of age-related chronic conditions there is uncertainty regarding its role in primary prevention people aged 70 years over. Aims To assess whether daily active treatment 100 mg enteric-coated aspirin will extend the duration disability-free life healthy older participants. Design A double-blind, randomized, placebo-controlled trial undertaken Australia United States with careful adjudication endpoints including stroke. Study...
Objective: To present normative performance data on the Modified Mini-Mental State (3MS) examination for healthy community-dwelling older individuals according to gender, age, education level, and ethno-racial group. Method: More than 19,000 generally men women without a diagnosis of dementia were recruited from general population in Australia U.S. ASPirin Reducing Events Elderly (ASPREE) study. The 3MS exam was administered as part baseline screening scoring above 77 eligible participate....
Abstract Prolonging survival in good health is a fundamental societal goal. However, the leading determinants of disability-free healthy older people have not been well established. Data from ASPREE, bi-national placebo-controlled trial aspirin with 4.7 years median follow-up, was analysed. At enrolment, participants were and without prior cardiovascular events, dementia or persistent physical disability. Disability-free outcome defined as absence dementia, disability death. Selection...
ABSTRACT Background: Not only is depression associated with increased inflammation but a risk factor for the genesis of depression. Many environmental factors are transduced through inflammatory signaling. Anti-inflammatory agents show promise management in preclinical, epidemiological, and early clinical studies. This opens door to potential anti-inflammatory treat prevent There no evidence-based pharmacotherapies prevention. Method: ASPREE-D, aspirin prevention elderly, sub study ASPREE,...
LettersMay 2022Safety of Ceasing Aspirin Used Without a Clinical Indication After Age 70 Years: A Subgroup Analysis the ASPREE Randomized TrialMark R. Nelson, MBBS(Hons), MFM, PhD, Galina Polekhina, MBiostat, Robyn L. Woods, BSc(Hons), Christopher M. Reid, MPH, Andrew Tonkin, MBBS, MD, Rory Wolfe, Anne Murray, MSc, Brenda Kirpach, CCRA, Michael E. Ernst, PharmD, Jessica Lockery, Raj C. Shah, Nigel Stocks, Suzanne G. Orchard, BSc (Hons), Zhen Zhou, PhDMark PhDMenzies Institute for Medical...
Abstract The Aspirin in Reducing Events the Elderly (ASPREE) Trial recruited 19,114 participants across Australia and United States during 2010–2014. Participants were randomized to receive either 100 mg of aspirin daily or matching placebo, with disability-free survival as primary outcome. During a median 4.7 years follow-up, 37% group permanently ceased taking their study medication 10% commenced open-label use. In placebo group, 35% 11% using use, respectively. order estimate...
Abstract Background Large-scale studies risk generating inaccurate and missing data due to the complexity of collection. Technology has potential improve quality by providing operational support collectors. However, this is under-explored in community-based trials. The Aspirin reducing events elderly (ASPREE) trial developed a suite that was specifically designed collectors: ASPREE Web Accessible Relational Database ( AWARD ). This paper describes impact system design on quality. Methods ’s...
Abstract Background The net benefit of aspirin cessation in older adults remains uncertain. This study aimed to use observational data emulate a randomized trial versus continuation without cardiovascular disease (CVD). Methods Post hoc analysis using target emulation framework applied the immediate post-trial period (2017–2021) low-dose initiation aged ≥ 70 years (ASPREE; NCT01038583). Participants from Australia and USA were included if they free CVD at start intervention (time zero, T0 )...